FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038049217> ?p ?o ?g. }

• W2038049217 endingPage "1254" @default.
• W2038049217 startingPage "1237" @default.
• W2038049217 abstract "Background: The comparative effects of biological response modifiers (BRMs) on the severity of psoriasis and its effects on health-related quality of life (HRQoL) have not been evaluated.Objective: To conduct a meta-analysis to assess the effects of available biological agents on the severity of psoriasis, as well as to provide data on the effects of these agents on HRQoL.Methods: Medline and other databases were searched for randomized controlled trials (≥ 10 weeks’ duration in adults) comparing biological therapies for moderate-to-severe psoriasis with placebo. A Mantel–Haenszel fixed-effects model was employed to estimate the pooled relative risks (RR) of patients achieving ≥ 75% reduction of baseline Psoriasis Area and Severity Index (PASI 75) after ≥ 10 weeks of treatment. Similar analyses were also conducted on PASI 50 and PASI 90. Using a random-effects model, we estimated the likelihood of achieving PASI 50, PASI 75, and PASI 90 at 10–12 weeks and 24 weeks. Data on the effects of different BRMs (vs. placebo) on HRQoL were also presented. Numbers (%) of patients discontinuing treatment were presented as a general index of drug tolerability.Results: Patients receiving infliximab 5 mg/kg intra­venously at weeks 0, 2, and 6, then every 8 weeks, had the highest RR of achieving PASI 75, with a pooled RR value of 25.48 (95% confidence interval [CI], 14.04–46.23); followed by etanercept 50 mg administered sub­cutaneously (SC) twice weekly with RR = 11.92 (95% CI, 8.17–17.39); etanercept 25 mg SC twice weekly with RR = 10.68 (95% CI, 6.15–18.57); efalizumab 1–2 mg/kg SC per week with RR = 7.47 (95% CI, 5.20–10.73); and alefacept administered weekly (various doses) with RR = 3.37 (95% CI, 2.18–5.23). (All RR values were estimated vs. placebo.) Similar findings were observed with regard to proportions of patients achieving PASI 50 and PASI 90. The random-effects analysis suggested that infliximab significantly increased the likelihood of achieving PASI 50, PASI 75, and PASI 90 compared with placebo at 10–12 weeks; however, there were no signif­icant differences between biological treatments at 24 weeks. Each BRM improved HRQoL compared with placebo according to findings from the Dermatology Life Quality Index. Proportions of patients discontinuing treatment were similar in active-treatment and placebo groups.Conclusions: Infliximab significantly reduced disease severity by both fixed- and random-effects models. All biological therapies improved HRQoL compared with placebo, and proportions of patients discontinuing treat­ment were similar in active-treatment and placebo groups. The analysis is potentially limited by statistical factors and did not systematically account for different toxicity profiles, but the findings establish a foundation for head-to-head comparative trials." @default.
• W2038049217 created "2016-06-24" @default.
• W2038049217 creator A5000572878 @default.
• W2038049217 creator A5012734924 @default.
• W2038049217 creator A5035044854 @default.
• W2038049217 creator A5049405030 @default.
• W2038049217 creator A5071626276 @default.
• W2038049217 creator A5078821076 @default.
• W2038049217 date "2008-03-19" @default.
• W2038049217 modified "2023-09-26" @default.
• W2038049217 title "Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis" @default.
• W2038049217 cites W1973201198 @default.
• W2038049217 cites W1975900036 @default.
• W2038049217 cites W1980773105 @default.
• W2038049217 cites W1980846675 @default.
• W2038049217 cites W1992633930 @default.
• W2038049217 cites W1995833857 @default.
• W2038049217 cites W2007076203 @default.
• W2038049217 cites W2012980289 @default.
• W2038049217 cites W2013361256 @default.
• W2038049217 cites W2019947683 @default.
• W2038049217 cites W2030298480 @default.
• W2038049217 cites W2030348118 @default.
• W2038049217 cites W2033275545 @default.
• W2038049217 cites W2034585843 @default.
• W2038049217 cites W2036488279 @default.
• W2038049217 cites W2038741370 @default.
• W2038049217 cites W2044221229 @default.
• W2038049217 cites W2045940178 @default.
• W2038049217 cites W2086861262 @default.
• W2038049217 cites W2091442391 @default.
• W2038049217 cites W2096991001 @default.
• W2038049217 cites W2098835966 @default.
• W2038049217 cites W2106686862 @default.
• W2038049217 cites W2126930838 @default.
• W2038049217 cites W2130925114 @default.
• W2038049217 cites W2134852288 @default.
• W2038049217 cites W2146843653 @default.
• W2038049217 cites W2152976783 @default.
• W2038049217 cites W2164533070 @default.
• W2038049217 cites W2168911501 @default.
• W2038049217 cites W2169787227 @default.
• W2038049217 cites W2170521505 @default.
• W2038049217 cites W2172257129 @default.
• W2038049217 cites W4233561050 @default.
• W2038049217 doi "https://doi.org/10.1185/030079908x291985" @default.
• W2038049217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18355421" @default.
• W2038049217 hasPublicationYear "2008" @default.
• W2038049217 type Work @default.
• W2038049217 sameAs 2038049217 @default.
• W2038049217 citedByCount "46" @default.
• W2038049217 countsByYear W20380492172012 @default.
• W2038049217 countsByYear W20380492172013 @default.
• W2038049217 countsByYear W20380492172014 @default.
• W2038049217 countsByYear W20380492172015 @default.
• W2038049217 countsByYear W20380492172016 @default.
• W2038049217 countsByYear W20380492172017 @default.
• W2038049217 countsByYear W20380492172018 @default.
• W2038049217 countsByYear W20380492172020 @default.
• W2038049217 countsByYear W20380492172021 @default.
• W2038049217 countsByYear W20380492172022 @default.
• W2038049217 countsByYear W20380492172023 @default.
• W2038049217 crossrefType "journal-article" @default.
• W2038049217 hasAuthorship W2038049217A5000572878 @default.
• W2038049217 hasAuthorship W2038049217A5012734924 @default.
• W2038049217 hasAuthorship W2038049217A5035044854 @default.
• W2038049217 hasAuthorship W2038049217A5049405030 @default.
• W2038049217 hasAuthorship W2038049217A5071626276 @default.
• W2038049217 hasAuthorship W2038049217A5078821076 @default.
• W2038049217 hasConcept C126322002 @default.
• W2038049217 hasConcept C142724271 @default.
• W2038049217 hasConcept C159110408 @default.
• W2038049217 hasConcept C16005928 @default.
• W2038049217 hasConcept C168563851 @default.
• W2038049217 hasConcept C17991360 @default.
• W2038049217 hasConcept C197934379 @default.
• W2038049217 hasConcept C204787440 @default.
• W2038049217 hasConcept C27081682 @default.
• W2038049217 hasConcept C2776173921 @default.
• W2038049217 hasConcept C2777011040 @default.
• W2038049217 hasConcept C2777138892 @default.
• W2038049217 hasConcept C2777226972 @default.
• W2038049217 hasConcept C2778375690 @default.
• W2038049217 hasConcept C2779134260 @default.
• W2038049217 hasConcept C2779951463 @default.
• W2038049217 hasConcept C2780564577 @default.
• W2038049217 hasConcept C30036603 @default.
• W2038049217 hasConcept C44249647 @default.
• W2038049217 hasConcept C71924100 @default.
• W2038049217 hasConcept C82789193 @default.
• W2038049217 hasConcept C95190672 @default.
• W2038049217 hasConceptScore W2038049217C126322002 @default.
• W2038049217 hasConceptScore W2038049217C142724271 @default.
• W2038049217 hasConceptScore W2038049217C159110408 @default.
• W2038049217 hasConceptScore W2038049217C16005928 @default.
• W2038049217 hasConceptScore W2038049217C168563851 @default.
• W2038049217 hasConceptScore W2038049217C17991360 @default.
• W2038049217 hasConceptScore W2038049217C197934379 @default.

• next